OncRef

Clinical Trial: NCT06049576

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Status:

SUSPENDED

Phase:

Phase 1

Lead Sponsor:City of Hope Medical Center
Information Provided By:City of Hope Medical Center
Last Update Posted:2026-10-08

Study Overview

Brief Summary

This phase I trial tests the safety, side effects, and best dose of camu camu when used in combination with nivolumab and ipilimumab in treating patients with kidney cancer that has spread to other places in the body. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Camu camu is a prebiotic that may have a beneficial effect on the immune system. Giving camu camu in combination with nivolumab and ipilimumab may kill more tumor cells than nivolumab and ipilimumab alone in patients with metastatic kidney cancer.

Official Title

Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell Carcinoma

Conditions

Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8

Intervention / Treatment

  • Procedure: Biospecimen Collection
  • Procedure: Bone Scan
  • Procedure: Computed Tomography
  • Biological: Ipilimumab
  • Procedure: Magnetic Resonance Imaging
  • Drug: Myrciaria dubia Prebiotic Supplement
  • Biological: Nivolumab

Other Study ID Numbers

  • 22457
  • NCI-2023-06703
  • 22457
  • P30CA033572

Start Date (Actual)

2023-10-06

Primary Completion Date (Estimated)

2027-05-25

Study Completion Date (Estimated)

2027-05-25

Enrollment (Actual)

31

Study Type

Interventional

Phase

Phase 1